NKTX News & Events

"This quarter marks an important milestone for Nkarta as we advance the NKX019 clinical program to treat autoimmune diseases," said Paul Hastings, CEO of Nkarta. "Following productive engagement with the FDA, we streamlined enrollment across our Ntrust-1 and Ntrust-2 clinical trials under a combined iDSMB, which has authorized initiation of the second dose-escalation cohort. This unified approach, combined with the ability to dose multiple patients simultaneously at each dose level and the removal of a patient-by-patient stagger, strengthens the efficiency of our trial enrollment and underscores the consistency of NKX019's emerging safety profile."

"We remain focused on the execution of our clinical trials and continue to believe in the differentiated potential of NK cell therapy to address unmet needs in the treatment of autoimmune diseases," said Paul Hastings, CEO of Nkarta. "Welcoming Dr. Rose and other key new members of our clinical team with rheumatology experience has provided us with world-class medical expertise to inform our ongoing enrollment of patients across our clinical studies and investigator-sponsored trials. Dr. Rose's track record as a seasoned rheumatologist, immunologist and accomplished drug developer in the autoimmune space will be invaluable as we continue to advance our NKX019 clinical trial programs."